UPL Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/r2aof73rw9fydqgzjysrjn0r.pdf

Key Takeaways


Demand & Channel Recovery

Mike Frank: "we believe that for the most part, in most regions, the destocking has been complete. And there's a good balance between what dealers and distributors are buying and what they're selling them to the farmers."

Margin Structure & Sustainability

Mike Frank: "we really believe that this is the margin profile going forward with the opportunity as we think about the next 12 and 24 months to continue to drive our new product launches, which are primarily in the differentiated and sustainable segment, which we know has a higher overall margin profile."

Regional Performance

RegionTrendCommentary
North America▲ Strong growthRevenue up 67% on strong demand, normalized channel inventories and rebates, and good s-metolachlor herbicide volumes.
Europe▲ Strong growthRevenue up 23% driven by strong fungicide volumes (Proxanil®) and NPP products, with margin expansion.
Latin America▲ Solid growthRevenue up 12% led by higher volumes of mancozeb and acephate-based products, partially offset by forex impact in Brazil; Evolution® and Feroce® improved differentiated volumes.
Rest of World▼ DeclineRevenue down 4% from pricing pressure in Africa, Australia and China; dollar-terms decline was less severe than the INR-terms drop.
UPL SAS (India)▲ RecoveryRevenue up 44% YoY on higher volumes, conscious placement closer to season, and lower Kharif returns; contribution margin improved 530 bps to 16.9%; EBITDA still marginally negative but improved sharply.
Advanta Seeds▬ MixedRevenue up 11% on higher volumes and better pricing, but margins contracted 615 bps on unfavorable crop mix and lower recoveries from higher input costs; EBITDA down 15%.

Balance Sheet & Cash Flow

Anand Vora: "This is for the first time in the recent period where our December net debt was lower than that of the previous quarter."

Product Portfolio & Innovation


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA growthDeliver 50% growth in EBITDA for the full yearFY25
Operating free cash flowGenerate US$300–400 million of operating FCFFY25
Net debt-to-EBITDAReduce to below 2x, with a range of 1.5x–2x or possibly below 1.5xFY25 exit
Q4 marginsSustain strong margins similar to Q3, driven by differentiated/sustainable mixQ4 FY25
CapexMaintain US$250–300 million range; FY25 spend expected below budget at INR1,500–1,600 croresFY25 and beyond
Interest cost reductionAt least 1.0%–1.25% reduction in SOFR during the calendar year; spreads to improve 35–50 bpsMid-July to August 2025 for spreads
Bank covenant ratchetIf net debt/EBITDA falls below 2x by March 2025 results, the 35–40 bps spread increase will be rolled backMarch 2025 results
Advanta stake sale closeCCI clearance expected; proceeds for debt repaymentEnd of February to mid-March 2025
Rights issue second callFirst call of INR844 crores approved January 24, record date January 30Expected by end of March 2025
Capital Markets DayProvide more color on FY26 and beyond business evolutionMay 2025

Key Metrics

MetricQ3 FY25
Revenue₹10,907 cr, +10% YoY; led by 9% volume growth, 5% pricing, offset by 4% forex
Contribution margin41.0%, ~1,400 bps jump YoY driven by product mix, COGS improvement, rebate normalization
EBITDA₹2,163 cr, 4x increase vs ₹416 cr in Q3 last year
EBITDA margin19.8%, ~1,600 bps increase from 4.2% YoY
Adjusted PAT₹828 cr vs loss of ₹1,217 cr in Q3 last year
Finance costs₹704 cr, marginally lower YoY due to drop in working capital and borrowings
Forex losses₹108 cr, sharp reduction from ₹613 cr in Q3 last year (which included Argentina devaluation)
Tax credit₹499 cr vs ₹59 cr last year; ₹592 cr provision reversed on favorable CIT(A) order for AY 2016-17
9-month revenue₹31,064 cr, +7% YoY; volumes +14%, price -5%, forex -2%
9-month EBITDA₹4,884 cr, +36% YoY; margins at 15.7%, up 340 bps
Full-year EBITDA growth guidance50% growth over previous year, maintained
Net working capital days107 days, reduction of 48 days YoY from 155 days
Gross debtUS$3.53 bn (₹30,244 cr), reduced by US$815 mn YoY
Net debt reductionUS$745 mn lower vs same period last year; US$264 mn lower vs September
Operating free cash flow guidanceUS$300 mn to US$400 mn for full year, maintained
Net debt-to-EBITDA target~2x for full financial year FY25
Global crop protection revenue growth+15% YoY, led by higher volumes in Latin America and Europe
Differentiated and sustainable volume growth+16% YoY
Latin America revenue growth+12% YoY, led by higher volumes offset by forex impact in Brazil
North America revenue growth+67% YoY, strong demand with channel inventories and rebates normalized
Europe revenue growth+23% YoY, driven by strong fungicide volumes and NPP products
Rest of World revenue growth-4% YoY, primarily from pricing pressure in Africa, Australia, China
New product launches revenue targetUS$85 mn expected for FY25
UPL SAS (India CP) revenue₹535 cr, +44% YoY driven by higher volumes
UPL SAS EBITDANegative ₹24 cr vs negative ₹70 cr last year
Advanta Seeds revenue growth+11% YoY, supported by higher volumes, better pricing, favorable FX
Advanta Seeds EBITDA₹223 cr, down 15% YoY due to lower contribution margin and strategic R&D, marketing investments
Capex spent YTD₹1,200 cr (includes Corteva Dithane® acquisition); full-year expected ₹1,500–₹1,600 cr vs ₹1,800 cr budget
Cost of debt~7% average across all debt instruments
Rights issue proceeds receivedUS$100 mn (₹844 cr) in Dec 2024; first call of another US$100 mn expected by March 2025
Advanta stake sale proceedsUS$350 mn total (US$100 mn primary, US$250 mn secondary for UPL debt repayment), expected within FY25